Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04540380 · ClinicalTrials.gov registry record · Phase 1
Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH
A Phase 1 study of Renal Failure, sponsored by Massachusetts General Hospital.
- Active
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT04540380 is a Phase 1 study of Renal Failure that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 20 participants, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04540380, a Phase 1 study of Renal Failure, is active but no longer recruiting, sponsored by Massachusetts General Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance immunosuppression.
Conditions Studied
Interventions
- DRUG Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab
- PROCEDURE Combined bone marrow and kidney transplant
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2027-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04540380
The ClinicalTrials.gov registry entry for NCT04540380 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 300-participant average among 11 other Renal Failure trials with a reported enrollment target (93% lower). The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Renal Failure appearing as the primary indexed condition, and to 2 interventions - of which Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab is the first listed.
NCT04540380 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT04540380 about?
NCT04540380 is a clinical study titled "Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH". The goal is to investigate the safety of the conditioning regimen, and its ability to induce donor/recipient lymphohematopoietic chimerism without Chimerism Transition Syndrome (CTS), which may result in donor-specific unresponsiveness (tolerance) to the renal allograft in the absence of maintenance...
What is the current status of trial NCT04540380?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-09-01. Estimated completion is 2027-06.
What conditions does trial NCT04540380 study?
This clinical trial studies the following conditions: Renal Failure.
What interventions are being tested in trial NCT04540380?
The interventions under investigation include: Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab (DRUG), Combined bone marrow and kidney transplant (PROCEDURE).
Who is sponsoring clinical trial NCT04540380?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04540380 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Post-Filter Hematocrit
RECRUITING · NA
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure
RECRUITING · Early Phase 1
-
Prevent Cardiac Surgery Associated AKI Trial
RECRUITING · Phase 2
-
Obesity Surgery and Kidney Transplant for Patients With Obesity and Renal Failure
COMPLETED · NA
-
Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.